Details for Patent: 11,065,237
Which drugs does patent 11,065,237 protect, and when does it expire?
Patent 11,065,237 protects VAFSEO and is included in one NDA.
This patent has fifty-six patent family members in twenty-four countries.
Summary for Patent: 11,065,237
| Title: | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| Abstract: | Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders. |
| Inventor(s): | James Densmore Copp, Ann W. Newman, Anne Luong |
| Assignee: | Akebia Therapeutics Inc |
| Application Number: | US16/786,187 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,065,237 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 11,065,237
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akebia | VAFSEO | vadadustat | TABLET;ORAL | 215192-001 | Mar 27, 2024 | RX | Yes | No | 11,065,237 | ⤷ Start Trial | Y | Y | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS | ⤷ Start Trial | ||
| Akebia | VAFSEO | vadadustat | TABLET;ORAL | 215192-002 | Mar 27, 2024 | RX | Yes | No | 11,065,237 | ⤷ Start Trial | Y | Y | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS | ⤷ Start Trial | ||
| Akebia | VAFSEO | vadadustat | TABLET;ORAL | 215192-003 | Mar 27, 2024 | DISCN | Yes | No | 11,065,237 | ⤷ Start Trial | Y | Y | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,065,237
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 099354 | ⤷ Start Trial | |||
| Argentina | 128483 | ⤷ Start Trial | |||
| Australia | 2014348523 | ⤷ Start Trial | |||
| Australia | 2019202144 | ⤷ Start Trial | |||
| Australia | 2020294308 | ⤷ Start Trial | |||
| Australia | 2022259767 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
